In this space, entities from any country can publish collaboration alerts.
Only those offers and requests related to R & D & i in the field of digital technologies will be published.
If you are interested in publishing offers or demands of your entity, complete the following form and send it to ptedisruptive@apte.org
Search for Spanish partners to collaborate in a project of molecular diagnostic services for the detection of antibiotic resistance with India.
The CDTI has announced a new partner search to locate Spanish companies interested in collaborating in an international joint innovation project with an Indian company in molecular diagnostic services for the detection of antibiotic resistance.
HORIZON-CL3-2021-DRS-01-05 partner search: Spanish engineering company looks for partners to join an international consortium to develop fast deployed mobile laboratory and lead the infrastructure laboratories.
Official deadline for the call: 23 November 2021 – Deadline for the EoI: 30 July 2021 Anticipated duration of the project: 36 Months
Spain based engineering company looks for partners to join an international consortium to develop fast deployed mobile laboratory to apply next HE CL3 call. Sought partner must be from EU or associated countries would lead an Infrastructure Work Package and be the designers and manufacturers of mobile infrastructure for laboratories, containers/shelters, flexible tents, equipment associated with safety and operation, electrical generation, biodecontamination and biowaste management.
The project aims to:
- Conduct an exhaustive review of solutions existing today both in structures and designs of mobile laboratories.
- Carry out an extensive evaluation and manufacturing of sampling, detection, and identification new technologies to achieve TRL 6-8 at project ending.
- Strategies to orchestrate mobile lab capacities in the EU, and improvements in the management of trained staff in Europe to increase the actual diagnostic capacity as close as possible to the crisis area. The project intends to find new sequencing technologies to help detect emerging agents and possible viral mutations that could represent a significant leap in terms of speed and cost.
